Plasma concentrations of CA 50,CA 12.5,CA 15.3 and CA 19.9 in endometrial cancer

1987 ◽  
Vol 28 ◽  
pp. 60
Author(s):  
S. Huber ◽  
P. Schmidt-Rhode ◽  
K.-D. Schulz ◽  
G. Sturm
Keyword(s):  
Endometrial Cancer ◽  
Plasma Concentrations ◽  
Ca 15.3 ◽  
Ca 19.9 ◽  
Ca 50

scholarly journals Prognostic role of neoplastic markers in Takotsubo syndrome

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Francesco Santoro ◽  
Tecla Zimotti ◽  
Adriana Mallardi ◽  
Alessandra Leopizzi ◽  
Enrica Vitale ◽  
...  
Keyword(s):  
Serum Levels ◽  
Takotsubo Syndrome ◽  
Ca 15.3 ◽  
Risk Of Death ◽  
Increased Risk ◽  
Ca 19.9 ◽  
Long Term Follow Up

AbstractTakotsubo syndrome (TTS) is an acute heart failure syndrome with significant rates of in and out-of-hospital mayor cardiac adverse events (MACE). To evaluate the possible role of neoplastic biomarkers [CA-15.3, CA-19.9 and Carcinoembryonic Antigen (CEA)] as prognostic marker at short- and long-term follow-up in subjects with TTS. Ninety consecutive subjects with TTS were enrolled and followed for a median of 3 years. Circulating levels of CA-15.3, CA-19.9 and CEA were evaluated at admission, after 72 h and at discharge. Incidence of MACE during hospitalization and follow-up were recorded. Forty-three (46%) patients experienced MACE during hospitalization. These patients had increased admission levels of CEA (4.3 ± 6.2 vs. 2.2 ± 1.5 ng/mL, p = 0.03). CEA levels were higher in subjects with in-hospital MACE. At long term follow-up, CEA and CA-19.9 levels were associated with increased risk of death (log rank p < 0.01, HR = 5.3, 95% CI 1.9–14.8, HR = 7.8 95% CI 2.4–25.1, respectively, p < 0.01). At multivariable analysis levels higher than median of CEA, CA-19.9 or both were independent predictors of death at long term (Log-Rank p < 0.01). Having both CEA and CA-19.9 levels above median (> 2 ng/mL, > 8 UI/mL respectively) was associated with an increased risk of mortality of 11.8 (95% CI 2.6–52.5, p = 0.001) at follow up. Increased CEA and CA-19.9 serum levels are associated with higher risk of death at long-term follow up in patients with TTS. CEA serum levels are correlated with in-hospital MACE.

Analytical Performance of Ca 19.9, Ca 125 and Ca 15.3 Assays as Observed through an External Quality Assessment Program

1994 ◽  
Vol 9 (1) ◽  
pp. 43-47 ◽  
Author(s):  
G.C. Zucchelli ◽  
A. Pilo ◽  
M.R. Chiesa ◽  
S. Masini ◽  
A. Clerico
Keyword(s):  
Monoclonal Antibody ◽  
Quality Control ◽  
Quality Assessment ◽  
External Quality Assessment ◽  
Ca 125 ◽  
External Quality ◽  
Ca 15.3 ◽  
Assessment Program ◽  
Ca 19.9 ◽  
Control Samples

Immunoassays of the tumor markers CA 19.9, CA125 and CA 15.3 are generally acknowledged to be a useful tool in the management of cancer patients. As a consequence, many methods developed by different companies are now commercially available. However, discrepancies have been described in the results of marker determinations even when the same monoclonal antibody was used. An external quality assessment (EQA) was carried out; starting from 1989 about 110 laboratories participated; since December 1991 the program was linked with the interlaboratory program Oncocheck organized by the Service de Radiopharmacie et Radioanalyse, University of Lyon. At present more than 200 laboratories of many European countries are involved: cumulatively 47 quality control samples have been prepared and sent to the participants. This manuscript is a report on data collected for CA 19.9, CA 125, and CA 15.3.

scholarly journals Stability of Tumor Markers CA 19.9, CA 125, and CA 15.3 in Serum Obtained from Plain Tubes and Tubes Containing Thixotropic Gel Separator

1997 ◽  
Vol 43 (12) ◽  
pp. 2430-2431 ◽  
Author(s):  
Giuseppe Banfi ◽  
Pierangela Parma ◽  
Marina Pontillo
Keyword(s):  
Tumor Markers ◽  
Ca 125 ◽  
Ca 15.3 ◽  
Ca 19.9

Insulin-Like Growth Factor 1/Mammalian Target of Rapamycin and AMP-Activated Protein Kinase Signaling Involved in the Effects of Metformin in the Human Endometrial Cancer

2016 ◽  
Vol 26 (9) ◽  
pp. 1667-1672 ◽  
Author(s):  
Dongge Cai ◽  
Hongli Sun ◽  
Yanhua Qi ◽  
Xiaogui Zhao ◽  
Minjuan Feng ◽  
...  
Keyword(s):  
Endometrial Cancer ◽  
Growth Factor ◽  
Protein Kinase ◽  
Molecular Mechanisms ◽  
Pilot Trial ◽  
Plasma Concentrations ◽  
Mammalian Target Of Rapamycin ◽  
Target Of Rapamycin ◽  
Insulin Like Growth Factor ◽  
Amp Activated Protein Kinase

BackgroundMetformin is a well-tolerated biguanide drug used for decades to treat type 2 diabetes mellitus. In recent years, long-term administration of metformin has been found to reduce carcinogenic risk for cancers derived from various tissues. However, its cellular and molecular mechanisms of anticancer action in the endometrial cancer (EC) have not yet been fully elucidated.Patients and MethodsSixty patients diagnosed as endometrial carcinoma were grouped into (n = 30) and non-treatment mixed (n = 30) for analysis. Thirty healthy donors are control groups. We attempt to investigate the interaction of metformin, insulin-like growth factor 1 (IGF-1) expression, and phosphorylated mammalian target of rapamycin (p-mTOR) and AMP-activated protein kinase (p-AMPK).ResultsWe found that high IGF-1 plasma concentrations in women with EC were reversed by conventional antidiabetic doses of metformin in the present work. In parallel, the activation of AMPK and suppression of mTOR seemed to play an important role for the effect of metformin in patients with EC.ConclusionsThis pilot trial presents biological evidence consistent with antiproliferative effects of metformin in women with EC in the clinical setting.

Analyzing Gastric Lavage of Gastric Cancer Patients: A Prospective Observational Study on Cytopathology and Determination of Intragastric CEA, CA 19.9, CA 72.4, and CA 50

2016 ◽  
Vol 60 (2) ◽  
pp. 161-166 ◽  
Author(s):  
Edoardo Virgilio ◽  
Enrico Giarnieri ◽  
Monica Montagnini ◽  
Rosaria D''Urso ◽  
Antonella Proietti ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Tumor Markers ◽  
Gastric Lavage ◽  
Control Group ◽  
Roc Curve Analysis ◽  
Cutoff Value ◽  
Ca 19.9 ◽  
Ca 50 ◽  
Gastric Cancer Patients

Objectives: To investigate gastric lavage (GL) cytopathology and immunometric analysis as novel clinicopathologic and prognostic parameters for gastric cancer (GC). Study Design: In 38 patients with gastric adenocarcinoma, we performed a cytopathologic analysis and an immunometric assay of GL using four tumor markers (CEA, CA 19.9, CA 72.4, and CA 50). The intragastric tumor marker levels were compared with a control group consisting of 41 non-GC patients to determine a statistically significant cutoff value. Results: GL cytopathology demonstrated the presence of cancer cells in 13 (34.2%) of the 38 GC patients: such a finding correlated to the parameters pT and pN with a statistically significant validity (p < 0.0267 and p < 0.0306, respectively). Measurement of intragastric CA 19.9 and CA 50 attained a statistically significant cutoff value (p < 0.002 and p < 0.0096, respectively), which was invalidated by the low sensitivity of the ROC curve analysis. Conclusions: In contrast to determination of its tumor markers, GL cytopathology correlated well with pT and pN staging parameters. Should this and other features be corroborated by future studies, the GL cytology test could be routinely used to detect aggressive types of GC even at early stages and result in important progress in the knowledge, staging, prediction, as well as management and follow-up of this inauspicious type of cancer.

scholarly journals Serum Tumor Markers may Precede Instrumental Response to Chemotherapy in Patients with Metastatic Cancer

2003 ◽  
Vol 18 (4) ◽  
pp. 295-300 ◽  
Author(s):  
C. Massacesi ◽  
M.B.L. Rocchi ◽  
F. Marcucci ◽  
A. Pilone ◽  
M. Galeazzi ◽  
...  
Keyword(s):  
Cancer Patients ◽  
Tumor Markers ◽  
Clinical Benefit ◽  
Instrumental Response ◽  
Metastatic Cancer ◽  
Ca 125 ◽  
Ca 15.3 ◽  
Serum Tumor Markers ◽  
Ca 19.9 ◽  
Pain Improvement

Purpose Although serum tumor markers (STMs) are widely used in clinical practice, their predictive role for the response to anticancer treatment is still controversial. The correlation of CEA, CA 15.3, CA 19.9, CA 125 (only with peritoneal involvement) and NSE levels with imaging response and clinical benefit was investigated in 60 non-selected patients with metastatic epithelial cancers treated by single-agent docetaxel chemotherapy. Methods STM measurement was performed at baseline and subsequently every three to four weeks. We applied the WHO criteria to evaluate both STM and instrumental responses. Concordance analysis was performed by the Cohen Kw index, and the significance of the results was established using the Fleiss, Cohen & Everitt test. Qualitative interpretation of data was obtained with the Landis & Koch scale. Correlations of STM response with clinical benefit (PS or pain improvement) were evaluated by the chi-square test. Results The primary tumors included breast cancers (38 patients), gastrointestinal non-colorectal cancers (12 patients), and lung cancers (10 patients). An overall significant good degree of agreement was observed between STM and instrumental response (p<0.0005). The degree of agreement for each marker was as follows: excellent for CEA (p<0.0005) and CA 125 (p=0.006), good for CA 15.3 (p<0.0005) and CA 19.9 (p=0.011). Restricted analysis for the correlation of each marker with primary tumor origin showed good prediction of radiological response for CA 15.3 and CEA in breast cancer patients (p<0.0005 for both), for CEA and CA 19.9 in gastrointestinal cancer patients (p=0.01 and 0.04, respectively), and for CEA+NSE in lung cancer patients (p=0.01). Conversely, STM response did not correlate significantly with the clinical benefit for the patients, both in terms of PS and pain improvement (p=0.24 and p=0.42, respectively). Conclusion This study showed STMs to be good predictors of tumor response. Although STMs cannot replace diagnostic imaging, in metastatic cancer they might be useful to optimize the timing of radiological re-evaluation in the palliative setting.

scholarly journals Tie-2, G-CSF, and Leptin as Promising Diagnostic Biomarkers for Endometrial Cancer: A Pilot Study

2021 ◽  
Vol 10 (4) ◽  
pp. 765
Author(s):  
Luka Roškar ◽  
Teja Klančič ◽  
Tamara Knific ◽  
Tea Lanišnik Rižner ◽  
Špela Smrkolj
Keyword(s):  
Endometrial Cancer ◽  
Pilot Study ◽  
Plasma Levels ◽  
Plasma Concentrations ◽  
Lower Grade ◽  
Neuropilin 1 ◽  
Precise Diagnosis ◽  
Extent Of Surgery ◽  
Grade 3

Preoperative determination of the extent of endometrial cancer (EC) would avoid the complications associated with radical surgery. Screening of patients’ plasma biomarkers might enable a more precise diagnosis of EC and a tailored treatment approach. This prospective case-control monocentric pilot study included 76 postmenopausal women (38 endometrioid EC patients and 38 control patients with benign gynecological conditions), and 37 angiogenic factors (AFs) were investigated as potential biomarkers for EC. AF concentrations in preoperative plasma samples were measured using Luminex xMAP™ multiplexing technology. The plasma levels of sTie-2 and G-CSF were significantly lower in EC compared to control patients, whereas the plasma levels of leptin were significantly higher in EC patients. Neuropilin-1 plasma levels were significantly higher in patients with type 2 EC (grade 3) compared to patients with lower grade cancer or controls. Follistatin levels were significantly higher in patients with lymphovascular invasion, and IL-8 plasma levels were significantly higher in patients with metastases. If validated, the plasma concentrations of the indicated AFs could represent an important additional diagnostic tool for the early detection and characterization of EC. This could guide the decision-making on the extent of surgery. Further studies with larger patient numbers are currently ongoing.

scholarly journals Valor diagnóstico de la combinación de nueve marcadores tumorales en neoplasias

2017 ◽  
Vol 1 (1) ◽  
pp. 19
Author(s):  
Ivón Howland Álvarez ◽  
Yolanda Cruz Gómez ◽  
Nairobi Fonseca Torres ◽  
Bárbara Dinorah Hidalgo Martínez ◽  
Viorkis Pérez Ortiz ◽  
...  
Keyword(s):  
Tumor Markers ◽  
Predictive Value ◽  
Clinical Laboratory ◽  
Reference Value ◽  
Ca 125 ◽  
Cytokeratin 19 ◽  
Neoplastic Disease ◽  
Ca 15.3 ◽  
Ca 19.9 ◽  
Marcadores Tumorales

Muchos  marcadores  tumorales  (MT)  no  son  específicos  a  un  tipo  particular  de  cáncer  y  el  nivel de uno de ellos puede aumentar como consecuencia de más de un tipo de cáncer, por lo que se utilizan en combinación para lograr mayor efectividad diagnóstica. Este trabajo se propone evaluar el valor diagnóstico de la combinación de nueve MT utilizados en diagnóstico de neoplasia tanto de forma individual como combinados. Se realizó un estudio retrospectivo entre enero 2013 y mayo de 2015 en el Laboratorio Clínico del Centro de Investigaciones Médico Quirúrgicas de La Habana a  100  pacientes  con  diagnóstico  de  cáncer  o  sospecha  clínica  de  neoplasia  oculta  a  quienes  se les  determinaron  los  marcadores  tumorales:  antígeno  carbohidrato  (CA)  19.9,  CA  72.4,  CA  125, CA  15.3,  antígeno  carcinoembrionario  (CEA),  componente  de  la  citoqueratina  19  (Cyfra  21-1), gonadotropina coriónica (HCG), ferritina y antígeno prostático de superficie (PSA). En todos los MT se observó un incremento del valor de corte sobre el valor límite superior de referencia mayor al 8%. En conjunto, la sensibilidad, especificidad, valor predictivo positivo (VPP) y valor predictivo negativo fueron de 23%, 99%, 96% y 51%, respectivamente. Para un valor de corte de 50 la especificidad y el VPP aumentaron a 99,6% y 97,5%, respectivamente. El uso de los 9 marcadores tumorales en conjunto mostró ser útil en el proceso de diagnóstico de pacientes con enfermedad neoplásica.  Palabras  clave:  marcadores  tumorales,  CA  19.9,  CA  72.4,  CA  125,  CA  15.3,  CEA,  Cyfra  21-1, HCG, Ferritina y PSA Abstract: Many  tumor  markers  are  not  specific  to  a  particular  type  of  cancer  and  the  level  of  one  of  them may increase as a result of more than one type of cancer, that’s why they are used in combination to achieve greater diagnostic effectiveness. This work aims to evaluate the diagnostic value of the combination of nine tumor markers commonly used in diagnosis of neoplasia both individually and in combination. A retrospective study from January 2013 to May 2015 was conducted at the Clinical Laboratory of the Center for Medical and Surgical Research in Havana, in 100 patients with cancer diagnosis or clinical suspicion of occult malignancy and to whom carbohydrate antigen (CA) 19.9, 72.4,  CA  125,  CA  15.3,  carcinoembryonic  antigen  (CEA),  component  cytokeratin  19  (CYFRA  21-1), chorionic gonadotropin (HCG), ferritin and prostate surface antigen (PSA) tumor markers were identified. An increase of cutoff value above the upper limit reference value in all higher TM 8% was observed. Overall, the sensitivity, specificity, positive predictive value (PPV) and negative predictive value were 23 %, 99 %, 96 % and 51 %, respectively. For a cut value of 50 specificity and PPV, they increased to 99.6% and 97.5%, respectively. The use of 9 tumor markers together showed to be useful in the process of diagnosing patients with neoplastic disease. Key words: tumor markers, CA 19.9, CA 72.4, CA 125, CA 15.3, CEA, Cyfra 21-1, HCG, Ferritina and PSA.

scholarly journals Valor diagnóstico de la combinación de nueve marcadores tumorales en neoplasias

2017 ◽  
Vol 1 (1) ◽  
pp. 19
Author(s):  
Ivón Howland Álvarez ◽  
Yolanda Cruz Gómez ◽  
Nairobi Fonseca Torres ◽  
Bárbara Dinorah Hidalgo Martínez ◽  
Viorkis Pérez Ortiz ◽  
...  
Keyword(s):  
Tumor Markers ◽  
Predictive Value ◽  
Clinical Laboratory ◽  
Reference Value ◽  
Ca 125 ◽  
Cytokeratin 19 ◽  
Neoplastic Disease ◽  
Ca 15.3 ◽  
Ca 19.9 ◽  
Marcadores Tumorales

Muchos  marcadores  tumorales  (MT)  no  son  específicos  a  un  tipo  particular  de  cáncer  y  el  nivel de uno de ellos puede aumentar como consecuencia de más de un tipo de cáncer, por lo que se utilizan en combinación para lograr mayor efectividad diagnóstica. Este trabajo se propone evaluar el valor diagnóstico de la combinación de nueve MT utilizados en diagnóstico de neoplasia tanto de forma individual como combinados. Se realizó un estudio retrospectivo entre enero 2013 y mayo de 2015 en el Laboratorio Clínico del Centro de Investigaciones Médico Quirúrgicas de La Habana a  100  pacientes  con  diagnóstico  de  cáncer  o  sospecha  clínica  de  neoplasia  oculta  a  quienes  se les  determinaron  los  marcadores  tumorales:  antígeno  carbohidrato  (CA)  19.9,  CA  72.4,  CA  125, CA  15.3,  antígeno  carcinoembrionario  (CEA),  componente  de  la  citoqueratina  19  (Cyfra  21-1), gonadotropina coriónica (HCG), ferritina y antígeno prostático de superficie (PSA). En todos los MT se observó un incremento del valor de corte sobre el valor límite superior de referencia mayor al 8%. En conjunto, la sensibilidad, especificidad, valor predictivo positivo (VPP) y valor predictivo negativo fueron de 23%, 99%, 96% y 51%, respectivamente. Para un valor de corte de 50 la especificidad y el VPP aumentaron a 99,6% y 97,5%, respectivamente. El uso de los 9 marcadores tumorales en conjunto mostró ser útil en el proceso de diagnóstico de pacientes con enfermedad neoplásica.  Palabras  clave:  marcadores  tumorales,  CA  19.9,  CA  72.4,  CA  125,  CA  15.3,  CEA,  Cyfra  21-1, HCG, Ferritina y PSA Abstract: Many  tumor  markers  are  not  specific  to  a  particular  type  of  cancer  and  the  level  of  one  of  them may increase as a result of more than one type of cancer, that’s why they are used in combination to achieve greater diagnostic effectiveness. This work aims to evaluate the diagnostic value of the combination of nine tumor markers commonly used in diagnosis of neoplasia both individually and in combination. A retrospective study from January 2013 to May 2015 was conducted at the Clinical Laboratory of the Center for Medical and Surgical Research in Havana, in 100 patients with cancer diagnosis or clinical suspicion of occult malignancy and to whom carbohydrate antigen (CA) 19.9, 72.4,  CA  125,  CA  15.3,  carcinoembryonic  antigen  (CEA),  component  cytokeratin  19  (CYFRA  21-1), chorionic gonadotropin (HCG), ferritin and prostate surface antigen (PSA) tumor markers were identified. An increase of cutoff value above the upper limit reference value in all higher TM 8% was observed. Overall, the sensitivity, specificity, positive predictive value (PPV) and negative predictive value were 23 %, 99 %, 96 % and 51 %, respectively. For a cut value of 50 specificity and PPV, they increased to 99.6% and 97.5%, respectively. The use of 9 tumor markers together showed to be useful in the process of diagnosing patients with neoplastic disease. Key words: tumor markers, CA 19.9, CA 72.4, CA 125, CA 15.3, CEA, Cyfra 21-1, HCG, Ferritina and PSA.

Sign in / Sign up

Export Citation Format

Share Document